# US 2025/0154101 A1 · Deuterated tryptamine derivatives and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154101 A1
- Document ID: US20250154101A1
- Status: Published application
- Kind: A1
- Application number: 19/020,095
- Filed: 2025-01-14
- Published: 2025-05-15
- Earliest claimed: 2020-05-19
- Assignees: Cybin IRL Limited
- Applicants: Cybin IRL Limited
- Inventors: Alex Nivorozhkin; Michael Palfreyman
- Web page: https://patentgrep.com/patent/US20250154101A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07D 209/16: Tryptamines
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C07F 9/572: Five-membered rings
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07B 2200/07: Optical isomers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

## Claims

### Claim at position 1

1-125. (canceled)

### Claim 126

A compound of Formula (I),
or an optically pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof,
wherein:
X1 and X2 are deuterium;
Y1 and Y2 are deuterium;
R is
R2 is selected from hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted allyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl;
R4 is selected from hydrogen and deuterium;
R5 is selected from hydrogen and deuterium;
R6 is selected from hydrogen and deuterium;
R7 is selected from hydrogen and deuterium;
R8 is an alkyl substituted with one or more deuterium;
R9 is an alkyl substituted with one or more deuterium; and
R10 is selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted allyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl.

### Claim 127 (depends on 126)

The compound of claim 126, wherein R is

### Claim 128 (depends on 126)

The compound of claim 126, wherein R is
and R10 is hydrogen.

### Claim 129 (depends on 126)

The compound of claim 126, wherein R2 is hydrogen or deuterium.

### Claim 130 (depends on 126)

The compound of claim 126, wherein R4 is hydrogen.

### Claim 131 (depends on 126)

The compound of claim 126, wherein R5 is hydrogen.

### Claim 132 (depends on 126)

The compound of claim 126, wherein R8 is methyl substituted with one or more deuterium.

### Claim 133 (depends on 132)

The compound of claim 132, wherein R8 is fully deuterated methyl (—CD3).

### Claim 134 (depends on 126)

The compound of claim 126, wherein R9 is methyl substituted with one or more deuterium.

### Claim 135 (depends on 134)

The compound of claim 134, wherein R9 is fully deuterated methyl (—CD3).

### Claim 136 (depends on 126)

The compound of claim 126, wherein R8 and R9 are methyl substituted with one or more deuterium.

### Claim 137 (depends on 136)

The compound of claim 136, wherein R8 and R9 are fully deuterated methyl (—CD3).

### Claim 138 (depends on 126)

The compound of claim 126, wherein:
R is
R2, R4, R5, R6, and R7 are hydrogen, and
R8 and R9 are methyl substituted with one or more deuterium.

### Claim 139 (depends on 126)

The compound of claim 126, which is in the form of a pharmaceutically acceptable salt.

### Claim 140 (depends on 139)

The compound of claim 139, wherein the pharmaceutically acceptable salt is a salt with an organic acid selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, fumaric acid, oxalic acid, maleic acid, citric acid, succinic acid, and tartaric acid.

### Claim 141 (depends on 139)

The compound of claim 139, wherein the pharmaceutically acceptable salt is a salt with fumaric acid.

### Claim 142 (depends on 139)

The compound of claim 139, wherein:
R is
R2, R4, R5, R6, and R7 are hydrogen, and
R8 and R9 are methyl substituted with one or more deuterium.

### Claim 143 (depends on 142)

The compound of claim 142, wherein R8 and R9 are fully deuterated methyl (—CD3).

### Claim 144 (depends on 143)

The compound of claim 143, wherein the pharmaceutically acceptable salt is a salt with an organic acid selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, fumaric acid, oxalic acid, maleic acid, citric acid, succinic acid, and tartaric acid.

### Claim 145 (depends on 143)

The compound of claim 143, wherein the pharmaceutically acceptable salt is a salt with fumaric acid.
